InChIKey	XUZMWHLSFXCVMG-UHFFFAOYSA-N
Compound Name	Baricitinib
Canonical SMILES	CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Clinical Status	Data-mined Candidate
Targets (Human+Pathogen)	24
Pfam Stratification	Cross-Family
Avg pChEMBL	6.89
Source	ChEMBL;BindingDB

DrugBank ID	DB11817
Drug Name	Baricitinib
CAS Number	1187594-09-7
Groups	approved investigational
ATC Codes	L04AF02
Description	Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib att...

---

Categories: Amides Antineoplastic and Immunomodulating Agents Antirheumatic Agents Azetines BCRP/ABCG2 Inhibitors BCRP/ABCG2 Substrates Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index Cytochrome P-450 Substrates Disease-modifying Antirheumatic Agents Drugs that are Mainly Renally Excreted Experimental Unapproved Treatments for COVID-19 Heterocyclic Compounds, Fused-Ring Immunosuppressive Agents Janus Kinase Inhibitor Janus Kinase Inhibitors MATE 2 Inhibitors MATE 2 Substrates MATE 2 Substrates with a Narrow Therapeutic Index MATE inhibitors MATE substrates Narrow Therapeutic Index Drugs OAT1/SLC22A6 inhibitors OAT3/SLC22A8 Inhibitors OAT3/SLC22A8 Substrates OAT3/SLC22A8 Substrates with a Narrow Therapeutic Index OATP1B3 inhibitors OCT2 Inhibitors P-glycoprotein substrates P-glycoprotein substrates with a Narrow Therapeutic Index Selective Immunosuppressants Sulfones Sulfur Compounds

---

Cross-references: BindingDB: 50021656 ChEBI: 95341 CHEMBL2105759 ChemSpider: 26373084 Drugs Product Database (DPD): 22971 D10308 PDB: 3JW PubChem:44205240 PubChem:347828164 RxCUI: 2047232 Wikipedia: Baricitinib ZINC: ZINC000073069247